title: A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm.
abstract: Adenosine contributes to the pathophysiology of respiratory disease, and adenosine challenge leads to bronchospasm and dyspnoea in patients. The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Therefore, it is proposed that inhibition of ENT1 in respiratory disease patients leads to increased adenosine concentrations, triggering bronchospasm and dyspnoea. This study aims to assess the translation of in vitro ENT1 inhibition to the clinical incidence of bronchospasm and dyspnoea in respiratory disease, cardiovascular disease and healthy volunteer populations. Four marketed drugs with ENT1 activity were assessed; dipyridamole, ticagrelor, draflazine, cilostazol. For each patient population, the relationship between in vitro ENT1 [3H]-NBTI binding affinity (Ki) and [3H]-adenosine uptake (IC50) to the incidence of: (1) bronchospasm/severe dyspnoea; (2) tolerated dyspnoea and; (3) no adverse effects, was evaluated. A high degree of ENT1 inhibition (≥13.3x Ki, ≥4x IC50) associated with increased incidence of bronchospasm/severe dyspnoea for patients with respiratory disease only, whereas a lower degree of ENT1 inhibition (≥0.1x Ki, ≥0.05x IC50) associated with a tolerable level of dyspnoea in both respiratory and cardiovascular disease patients. ENT1 inhibition had no effect in healthy volunteers. Furthermore, physicochemical properties correlative with ENT1 binding were assessed using a set of 1625 diverse molecules. Binding to ENT1 was relatively promiscuous (22% compounds Ki<1μM) especially for neutral or basic molecules, and greater incidence tracked with higher lipophilicity (clogP >5). This study rationalises inclusion of an assessment of ENT1 activity during early safety profiling for programs targeting respiratory disorders.
authors.affiliation: Discovery Safety, Drug Safety and Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, United Kingdom. Electronic address: Lyn.Rosenbrierribeiro@AstraZeneca.com.
authors.forename: Lyn
authors.initials: L
authors.lastname: Rosenbrier Ribeiro
authors.affiliation: Discovery Safety, Drug Safety and Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Ian Storer
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001986:Bronchial Spasm / Q000188:drug therapy / Q000453:epidemiology*; D000077407:Cilostazol; D002986:Clinical Trials as Topic / Q000379:methods; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use; D004417:Dyspnea / Q000188:drug therapy / Q000453:epidemiology*; D033721:Equilibrative Nucleoside Transporter 1 / Q000037:antagonists & inhibitors*; D006801:Humans; D015994:Incidence; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077486:Ticagrelor; D057170:Translational Research, Biomedical / Q000379:methods*
chemical_list: D033721:Equilibrative Nucleoside Transporter 1; D010879:Piperazines; C438649:SLC29A1 protein, human; D013777:Tetrazoles; C072040:draflazine; D004176:Dipyridamole; D000077486:Ticagrelor; D000241:Adenosine; D000077407:Cilostazol
keywords: Bronchospasm; Dyspnoea; ENT1; Off-target pharmacology; Respiratory disease; Translation